Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
New and emerging therapeutic options for thyroid carcinoma
Jatin P. Shah
, Gary L. Clayman
, Lori J. Wirth
Head & Neck Surgery
Research output
:
Contribution to journal
›
Article
›
peer-review
1
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New and emerging therapeutic options for thyroid carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Therapeutic Potential
100%
Thyroid Carcinoma
100%
New Therapeutics
100%
Refractory Disease
100%
Emerging Therapeutics
100%
Radioactive Iodine Refractory
100%
Tumor
66%
Adjuvant Therapy
66%
Thyroid Cancer
66%
Clinical Development
33%
Tumor Subtype
33%
Poor Prognosis
33%
Good Prognosis
33%
Targeted Therapy
33%
U.S. Food
33%
Management Plan
33%
Initial Treatment
33%
Poorly Differentiated Carcinoma
33%
Surgery Therapy
33%
Prognostic Risk Factors
33%
Sorafenib
33%
Aggressive Variant
33%
Systemic Agents
33%
Radioactive Iodine
33%
Systemic Targeted Therapy
33%
Differentiated Thyroid Cancer
33%
Aggressive Surgery
33%
Well-differentiated Carcinoma
33%
Radioiodine-refractory Differentiated Thyroid Cancer
33%
Lenvatinib
33%
Insular Carcinoma
33%
Patient Will
33%
Tall Cell Carcinoma
33%
Medicine and Dentistry
Thyroid Carcinoma
100%
Radioactive Iodine
100%
Carcinoma
80%
Diseases
60%
Thyroid Cancer
60%
Adjuvant Therapy
40%
Tumor
40%
Neoplasm
20%
Systemic Therapy
20%
Targeted Therapy
20%
Sorafenib
20%
Differentiated Thyroid Cancer
20%
Lenvatinib
20%